ImportRefusal LogoImportRefusal

Violation Code: 75

FDA Violation

Charge Code: UNAPPROVED

73,905
Total Refusals
26150
Affected Firms
12/31/2025
Latest Case
10/3/2001
First Case

Violation Details

Violation Code (ASC ID)
75
Charge Code
UNAPPROVED
Description
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
Legal Section
505(a), 801(a)(3); UNAPPROVED NEW DRUG

Most Affected Firms

#Firm NameLocationCases
1Wicks Pharmaceuticals Pvt LtdBangalore, INDIA576
2DREAM COSMETICSAbigian, IVORY COAS409
3Laboratorios PiSA, S.A. de C.V (Planta Tlajomulco)Tlajomulco De Zuniga, MEXICO379
4Nouvelle Parfumeria GandourAbidjan 01, IVORY COAS311
5Sanofi-Aventis US LLCSaint Louis, UNITED STA196
6NOVO NORDISKMississauga, CANADA191
7A.H. GEIGERLorrach, GERMANY177
8Novo Nordisk A/SBagsvard, DENMARK172
9Chemo S.A. Lugano BranchLugano, SWITZERLAN171
10PATANJALI AYURVED LIMITEDHaridwar, INDIA169
11PLANTAS MEDICINALES DE MEXICODELEGACION XOCHIMILCO C.P, MEXICO169
12NATURE REPUBLIC CO., LTD.Seoul, SOUTH KORE154
13Wendt-Chemie Vertriebsges Mbh & Co.Hamburg, GERMANY151
14Productos Maver, S.A. de C.V.Tlaquepaque, MEXICO146
15Merck, S.A. de C.V.Naucalpan De Juarez, MEXICO137
16SKYLINE HANDELS GMBHVienna, AUSTRIA135
17Apotex Inc.North York, CANADA128
18OMEGA NUTRITIONHidalgo Del Parral, MEXICO127
19TerravitaBrampton, CANADA119
20Biologische Heilmittel Heel GmbhBaden-Baden, GERMANY118

Recent Import Refusals

DateProductFirm
12/31/2025
RISANKIZUMAB-RZAA
58MCY09
12/31/2025
TIRZEPATIDE (ANTI-DIABETIC)
61PDY74
12/31/2025
TIRZEPATIDE (ANTI-DIABETIC)
61PCK74
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99
12/31/2025
MISCELLANEOUS PATENT MEDICINES, ETC.
66VCY99

Related Violations

Other violations under the same legal section: 505(a), 801(a)(3); UNAPPROVED NEW DRUG

CodeCharge CodeCases
3874708NEWDRUG5

Frequently Asked Questions

What is FDA violation code 75?

75 is an FDA violation code that indicates: "The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).". This violation is based on 505(a), 801(a)(3); UNAPPROVED NEW DRUG of the Federal Food, Drug, and Cosmetic Act.

How many import refusals have been issued for violation 75?

According to FDA Import Refusal data, there have been 73905 import refusals issued for violation code 75, affecting 26150 unique firms.

When was the most recent refusal for violation 75?

The most recent import refusal for violation 75 was on December 31, 2025.

What products are commonly refused for violation 75?

Products commonly refused under violation 75 include: RISANKIZUMAB-RZAA, TIRZEPATIDE (ANTI-DIABETIC), MISCELLANEOUS PATENT MEDICINES, ETC.. These products were refused entry because they did not meet FDA requirements.

What is the legal basis for FDA violation code 75?

Violation code 75 is based on 505(a), 801(a)(3); UNAPPROVED NEW DRUG of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This section of the law establishes requirements that imported products must meet to be allowed entry into the United States.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.